Brief: AIM Vaccine Initiates Randomized, Blinded And Comparable Vaccine-Controlled Phase III Trial
29/08/2023 14:30
Aug 29 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* INITIATION OF RANDOMIZED, BLINDED AND COMPARABLE
VACCINE-CONTROLLED PHASE III CLINICAL TRIAL
* PHASE III CLINICAL TRIAL OF 23-VALENT PNEUMOCOCCAL
POLYSACCHARIDE VACCINE
Source text for Eikon: ID:nHKS527lw5
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine